Perspective Therapeutics outlines $45B cancer market

Perspective Therapeutics, Inc. (CATX) reported that it updated its corporate presentation, which has been furnished as an exhibit.

Rhea-AI Filing Summary

Perspective Therapeutics, Inc. (CATX) reported that it updated its corporate presentation, which has been furnished as an exhibit. The presentation outlines a strategy focused on next‑generation radiopharmaceutical therapy in targeted oncology built around lead‑212 (²¹²Pb) payloads.

The company highlights three independent clinical‑stage programs targeting distinct receptors or antigens: VMT-α-NET for SSTR2+ neuroendocrine tumors, VMT01 for melanoma via MC1R, and PSV359 for FAP-ɑ–expressing solid tumors, along with a CCK2R program. The materials describe an estimated $45 billion+ combined solid tumor addressable market for programs VMT-α-NET, VMT01, PSV359, and PSV594, ongoing Phase 1/2a trials, clinical data expected in 2026 including ASCO 2026 analyses, and an integrated platform covering isotope production, regional manufacturing, and intellectual property across the radiopharmaceutical value chain.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Addressable market for VMT-α-NET, VMT01, PSV359 and PSV594: $45+ billion Clinical-stage programs: 3 programs Patients with creatinine follow-up: 68 patients +1 more

4 metrics

Addressable market for VMT-α-NET, VMT01, PSV359 and PSV594 $45+ billion Combined solid tumor market described for these radiopharmaceutical programs

Clinical-stage programs 3 programs Three independent clinical-stage programs, each against a distinct target

Patients with creatinine follow-up 68 patients Blood creatinine followed during VMT-α-NET treatment safety analysis

Clinical data timing 2026 Company references data in 2026 including ASCO 2026 analyses

Key Terms

Radiopharmaceutical Therapy, radioligand therapy, theranostic approach, immune checkpoint inhibitors, +1 more

5 terms

Radiopharmaceutical Therapy medical

"Radiopharmaceutical Therapy: A Category Still Early in Its Adoption Curve"

A medical treatment that links a tiny radioactive particle to a molecule that seeks out specific cells, delivering radiation directly to diseased tissue much like a guided missile hits a target while sparing nearby healthy areas. Investors pay attention because these therapies combine drug development with specialized manufacturing, regulatory review, and complex hospital delivery, so clinical success, production capacity, safety rules, and pricing can strongly influence a company’s growth and risk profile.

radioligand therapy medical

"VMT-α-NET: Potential First-in-Class 212Pb-Radioligand Therapy Targeting SSTR2"

A treatment that uses a small molecule or antibody designed to seek out specific cells and deliver a tiny dose of radiation directly to them, like a guided missile carrying a limited explosive to a particular target rather than carpeting an area. Investors care because successful radioligand therapies can become high-value prescription products with clear market niches, regulatory hurdles, and reimbursement decisions that strongly affect a developer’s revenue and risk profile.

theranostic approach medical

"Advancing a Theranostic Approach Direct-to-Hospital Delivery"

immune checkpoint inhibitors medical

"212Pb Uniquely Suited for Combination with Immune Checkpoint Inhibitors"

Drugs that release the immune system’s natural “brakes,” allowing immune cells to recognize and attack cancer cells; imagine taking the safety off a guard dog so it can chase intruders. They matter to investors because they can become high-value treatments with large sales potential, but their commercial success depends on clinical trial results, regulatory approval, competition and side-effect management, which all affect a company’s valuation.

SSTR2+ neuroendocrine tumors medical

"SSTR2+ Neuroendocrine Tumors is a Large, Growing Market"

FAQ

What did Perspective Therapeutics (CATX) announce in this 8-K?

Perspective Therapeutics updated its corporate presentation and furnished it as an exhibit. The presentation summarizes its 212Pb-based radiopharmaceutical pipeline, clinical development plans, manufacturing platform, and market opportunity in targeted oncology.

What is the stated market opportunity for CATX’s lead programs?

The company states that VMT-α-NET, VMT01, PSV359, and PSV594 together address a $45 billion+ solid tumor market. This figure reflects the combined addressable market for these radiopharmaceutical programs in targeted oncology.

How many clinical-stage programs does Perspective Therapeutics (CATX) highlight?

The presentation highlights three independent clinical-stage programs, each directed at a distinct target: VMT-α-NET for SSTR2+ neuroendocrine tumors, VMT01 for melanoma via MC1R, and PSV359 targeting FAP-ɑ in advanced solid tumors.

What clinical timing does CATX reference for its radiopharmaceutical programs?

Perspective Therapeutics references data in 2026, including analyses presented at ASCO 2026 for VMT-α-NET. These timing references relate to ongoing Phase 1/2a studies and planned data readouts described in the corporate presentation.

Which cancer indications are targeted by CATX’s VMT-α-NET and VMT01 programs?

VMT-α-NET targets SSTR2+ neuroendocrine tumors, a large and growing market with described unmet need. VMT01 targets melanoma through the MC1R receptor, including in patients treated with immune checkpoint inhibitors.

What platform and manufacturing capabilities does CATX describe?

Perspective Therapeutics describes an integrated platform including structural chemistry optimization, selection of the ²¹²Pb isotope, a theranostic approach, and direct-to-hospital delivery via regional isotope production sites, supported by a stated IP portfolio across the value chain.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 05:17 PM Accepted by SEC EDGAR 09/08/2026 - 05:16 PM Learn about SEC filing dates

false000072838700007283872026-09-082026-09-08

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 08, 2026

Perspective Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-33407	41-1458152
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
c/o Perspective Therapeutics, Inc. 2401 Elliott Avenue Suite 320
Seattle, Washington				98121
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (206) 676-0900

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		CATX		NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On September 8, 2026, Perspective Therapeutics, Inc. updated its corporate presentation. A copy of the presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Corporate Presentation.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			PERSPECTIVE THERAPEUTICS, INC.
Date:	September 8, 2026	By:	/s/ Joel Sendek
			Joel Sendek Chief Financial Officer

Next-Generation Radiopharmaceuticals Redefining Targeted Oncology

Designed to be the Most Potent Payload in Targeted Oncology

Three Independent Clinical-Stage Programs, Each Against a Distinct Target with Data in 2026

Deep Leadership Across Radiopharmaceutical and Drug Development

The Perspective Story in Four Parts

Radiopharmaceutical Therapy: A Category Still Early in Its Adoption Curve

Radiopharmaceutical Therapy Is the Next Generation of Targeted Oncology

$45 Billion+ Addressable Market, Already Generating Blockbuster Radiopharmaceutical Revenue

VMT-α-NET, VMT01, PSV359, and PSV594 Address a Combined $45B+ Solid Tumor Market

Pipeline in Depth: The Data Behind Each Program

Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals

Neuroendocrine TumorsVMT-α-NET

SSTR2+ Neuroendocrine Tumors is a Large, Growing Market with Significant Unmet Need

VMT-α-NET: Potential First-in-Class 212Pb-Radioligand Therapy Targeting SSTR2

Ongoing Phase 1/2a to Establish Broad Therapeutic Window for VMT-α-NET

Patient Exposure and Follow-up with [212Pb]VMT-α-NET in ASCO 2026 Data Analysis

VMT-α-NET Best Response Deepens Over Time

VMT-α-NET Responses Deepen Over Time

Spider Plot of Tumor Change Over Time by Patient

VMT-⍺-NET: Durable Disease Control Across All Doses

Best-in-class Safety Profile1

Blood Creatinine During Follow-up for All Patients Treated (n=68)

VMT-α-NET ’s Compelling Profile Supports Potential Registration Study at Current Dose Level

MelanomaVMT01

Checkpoint Inhibitors Transformed Care of Melanoma but Leave Many Patients Behind

VMT01: Potential First-in-Class 212Pb Therapy Targeting MC1R for Melanoma

Ongoing Phase 1/2a Open-Label Trial For VMT01 in Melanoma

Preliminary Anti-tumor Activity Observed at 3.0 mCi Dose of VMT01

Treatment Emergent Adverse Events (All Grades, Occurring in ≥ 10% of Patients)

VMT01 Clinical Data Support Further Development

PSV359Advanced Solid Tumors

PSV359: Potential First-in-Class 212Pb Therapy Targeting FAP-ɑ for Solid Tumors

FAP-ɑ is an Attractive Cancer Target with Broad Solid Tumor Potential

Ongoing Open-label Phase 1/2a Trial For PSV359 in Advanced Solid Tumors

PSV359 has Improved Tumor Retention, Highlighting its Potential as a Therapeutic Agent

CCK2R81 a potential first-in-class in selected solid tumors

Perspective’s CCK2R81 in Medullary Thyroid Cancer Compared to FDG and Fluorodopa

Platform and Manufacturing

Optimizing Structural Chemistry:

Choosing the Right Isotope

Not All ²¹²Pb Programs Are Created Equal

Advancing a Theranostic Approach:

Direct-to-Hospital Delivery through Integrated Isotope Production

Reaching the Largest Addressable Market with Regional Manufacturing

Financial Strength and IP

Strong IP Portfolio Covering All Aspects of Radiopharmaceutical Value Chain

A Decade of Deliberate, End-to-End Engineering

Built Over a Decade - The Platform Is Built; Pipeline Advancing

Abbreviations

APPENDIX – Backup Slides

Investment thesis

Engineering the Alpha Advantage in Targeted Oncology

Optimizing the Entire System for Targeted Oncology

Advancing a Diverse 212Pb-Based Oncology Portfolio

Market opportunity

Solid Tumors are an Attractive Market for Radiopharmaceuticals

NETs Trials

Refractory Metastatic Melanoma Trials

VMT-α-NET

VMT-⍺-NET: Baseline Patient Characteristics in ASCO 2026 Data Analysis

Patient with Confirmed PR After [212Pb]VMT-α-NET Treatment

VMT01

ICI Combo Rationale: Strong Synergy with VMT01 in Melanoma

Metastatic Melanoma: Confirmed Partial Response after 2 Cycles of [212Pb]VMT01

Platform and Manufacturing

Construct Designed for Better Clinical Outcome

212Pb Uniquely Suited for Combination with Immune Checkpoint Inhibitors

Kinetics Matter: 212Pb Hits Hard and Fast for Strong Activity with Less Systemic Exposure

Daily Production at Regional Sites Ensures Supply of Ready-to-Administer Product

IP protection

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 26.5 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 25.3 KB